We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+51.8%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$360M
AUM Growth
+$24.1M
Cap. Flow
-$43.1M
Cap. Flow %
-11.96%
Top 10 Hldgs %
41.39%
Holding
100
New
33
Increased
9
Reduced
32
Closed
23

Top Buys

Rank Stock Value
1
CCCC icon
C4 Therapeutics
CCCC
+$11.1M
2
RNAM
Avidity Biosciences
RNAM
+$7.67M
3
CATX icon
Perspective Therapeutics
CATX
+$6.91M
4
SLDB icon
Solid Biosciences
SLDB
+$6.83M
5
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$6.54M

Top Sells

Rank Stock Value
1
MRSN
Mersana Therapeutics
MRSN
+$13.7M
2
MGNX icon
MacroGenics
MGNX
+$11.8M
3
MDT icon
Medtronic
MDT
+$11.1M
4
SNY icon
Sanofi
SNY
+$10.9M
5
RCKT icon
Rocket Pharmaceuticals
RCKT
+$8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRYS icon
51
Krystal Biotech
KRYS
$10.1B
$1.78M 0.49%
+10,000
New +$1.39M
MODD icon
52
Modular Medical
MODD
$12.9M
$1.67M 0.46%
+30,000
New +$1.61M
TERN
53
DELISTED
Terns Pharmaceuticals
TERN
$1.64M 0.46%
250,551
-266,448
-52% -$1.74M
VKTX icon
54
Viking Therapeutics
VKTX
$3.7B
$1.64M 0.46%
+20,000
New +$890K
AMLX icon
55
Amylyx Pharmaceuticals
AMLX
$2.26B
$1.42M 0.39%
+500,000
New +$6.54M
CRBP icon
56
Corbus Pharmaceuticals
CRBP
$166M
$1.25M 0.35%
+31,980
New +$789K
GUTS icon
57
Fractyl Health
GUTS
$109M
$1.23M 0.34%
+166,666
New +$1.4M
CCCC icon
58
CALL
C4 Therapeutics
CCCC
$385M
$1.23M 0.34%
+150,000
New +$1.16M
ETNB
59
DELISTED
89bio
ETNB
$1.07M 0.3%
92,298
-66,421
-42% -$735K
ABVX
60
Abivax
ABVX
$10.9B
$1.07M 0.3%
+75,000
New +$967K
ZURA icon
61
Zura Bio
ZURA
$516M
$844K 0.23%
328,504
-134,493
-29% -$477K
KPTI icon
62
Karyopharm Therapeutics
KPTI
$43.5M
$843K 0.23%
37,231
-233
-0.6% -$4.08K
GERN icon
63
Geron
GERN
$828M
$825K 0.23%
+250,000
New +$560K
MTEM
64
DELISTED
Molecular Templates, Inc.
MTEM
$794K 0.22%
354,608
– –
ACET icon
65
Adicet Bio
ACET
$85.2M
$779K 0.22%
+20,705
New +$857K
MLYS icon
66
Mineralys Therapeutics
MLYS
$2.25B
$735K 0.2%
+56,944
New +$703K
ALGS icon
67
Aligos Therapeutics
ALGS
$26.2M
$642K 0.18%
26,221
-519
-2% -$10.3K
RLMD icon
68
Relmada Therapeutics
RLMD
$557M
$462K 0.13%
99,379
-621
-0.6% -$2.99K
ERAS icon
69
Erasca
ERAS
$6.3B
$461K 0.13%
+223,845
New +$447K
GPCR icon
70
Structure Therapeutics
GPCR
$3.41B
$429K 0.12%
+10,000
New +$422K
RZLT icon
71
Rezolute
RZLT
$454M
$388K 0.11%
151,985
-5,100
-3% -$7.26K
YARW
72
Yarrow Bioscience, Inc. Common Stock
YARW
$23.4M
$265K 0.07%
+1,728
New +$186K
ELUT icon
73
Elutia
ELUT
$37.9M
$248K 0.07%
+78,580
New +$273K
IMNM icon
74
Immunome
IMNM
$2.58B
$185K 0.05%
+7,489
New +$152K
AMLX icon
75
CALL
Amylyx Pharmaceuticals
AMLX
$2.26B
$56.8K 0.02%
+20,000
New +$262K
1 2
3
4

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return
ADIC
Abu Dhabi Investment Council Abu Dhabi, United Arab Emirates $975M AUM
PCM
Politan Capital Management New York $985M AUM 3.12% 1-Year Est. Return

Silverarc Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, Silverarc Capital Management held 100 positions worth $360M, up 7.2% from $336M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Silverarc Capital Management withdrew a net $43.1M in Q1 2024, closing 23 positions and reducing 32 holdings. Its most notable exit was Medtronic, an estimated $11.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 96% a quarter earlier.

Against the trend, Silverarc Capital Management opened a new position in C4 Therapeutics worth $11.7M.

  • Silverarc Capital Management's largest Q1 2024 buy was C4 Therapeutics: 1,435,931 shares worth $11.7M.
  • Silverarc Capital Management added most to Solid Biosciences in Q1 2024, an estimated $6.83M increase.
  • Silverarc Capital Management's biggest Q1 2024 reduction was Mersana Therapeutics, cutting an estimated $13.7M.
  • Silverarc Capital Management fully exited Medtronic in Q1 2024, selling an estimated $11.1M.
  • Silverarc Capital Management's ten largest holdings make up 41% of its $360M portfolio in Q1 2024.
  • Silverarc Capital Management opened 33 new positions and closed 23 in Q1 2024.
  • Silverarc Capital Management's portfolio value rose 7.2% quarter-over-quarter to $360M.

Based on Silverarc Capital Management's 13F filing for Q1 2024, filed 15 May 2024.